# First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-in-human-phase-1-2a-study-of-a-potent-and-novel-cdk2-selective-inhibitor/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Timothy A. Yap,Abdelaziz M. Elhaddad,Rachel N. Grisham,John Hamm,Douglas K. Marks,Geoffrey I. Shapiro,Christophe Le Corre,Jerry Li,Tun Tun Lin,Feng Liu,Lara Malky,Allison Moreau,Heather Neumann,Dejan Juric,Manish Sharma |
| Citations | 57 |
| DOI | 10.1200/jco.2023.41.16_suppl.3010 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4379283080 |
| Type | conference-abstract |
| Year | 2023 |

## Paper authors

- [Feng Liu](https://scholariq.org/researchers/feng-liu/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Paper topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.